TIL (Instil Bio) Net Change in Cash : $-3.64 Mil (TTM As of Sep. 2024)

View and export this data going back to 2021. Start your Free Trial

What is Instil Bio Net Change in Cash?

Net Change in Cash is calculated as the total of Cash Flow from Operations , Cash Flow from Investing, Cash Flow from Financing, and Effect of Exchange Rate Changes.

Instil Bio's Net Change in Cash for the three months ended in Sep. 2024 was $-0.28 Mil. Its Net Change in Cash for the trailing twelve months (TTM) ended in Sep. 2024 was $-3.64 Mil.

Instil Bio Net Change in Cash Historical Data

The historical data trend for Instil Bio's Net Change in Cash can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Instil Bio Net Change in Cash Chart

Instil Bio Annual Data

Trend

Dec19

Dec20

Dec21

Dec22

Dec23

Net Change in Cash

8.90

232.87

-203.67

5.63

-33.02

Instil Bio Quarterly Data
	Dec19	Mar20	Jun20	Sep20	Dec20	Mar21	Jun21	Sep21	Dec21	Mar22	Jun22	Sep22	Dec22	Mar23	Jun23	Sep23	Dec23	Mar24	Jun24	Sep24
Net Change in Cash	Get a 7-Day Free Trial															-12.78	0.55	-5.21	1.30	-0.28

Instil Bio Net Change in Cash Calculation

Instil Bio's Net Change in Cash for the fiscal year that ended in Dec. 2023 is calculated as

Net Change in Cash	=	Cash Flow from Operations	+	Cash Flow from Investing	+	Cash Flow from Financing	+	Effect of Exchange Rate Changes
	=	-82.029	+	41.128	+	8.082	+	-0.201
	=	-33.02

Instil Bio's Net Change in Cash for the quarter that ended in Sep. 2024

Net Change in Cash = Cash Flow from Operations + Cash Flow from Investing + Cash Flow from Financing + Effect of Exchange Rate Changes

= -20.133 + 19.814 + 0 + 0.042

= -0.28

Net Change in Cash for the trailing twelve months (TTM) ended in Sep. 2024 adds up the quarterly data reported by the company within the most recent 12 months, which was $-3.64 Mil.

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Instil Bio Net Change in Cash Related Terms
Thank you for viewing the detailed overview of Instil Bio's Net Change in Cash provided by GuruFocus.com. Please click on the following links to see related term pages.

Instil Bio Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Instil Bio Inc (NAS:TIL) » Definitions » Net Change in Cash

Comparable Companies

CTCX CLSD SLDB CRDF MEIP CLNN RANI BIOR LGVN IMUX OCSE:NOVO B VRTX REGN ASX:CSL SGEN XKRX:207940 MRNA XBRU:ARGX HKSE:02269 BNTX

Traded in Other Exchanges

N/A

Address

3963 Maple Avenue, Suite 350, Dallas, TX, USA, 75219

Website

https://www.instilbio.com

Instil Bio Inc is a clinical-stage biopharmaceutical company focused on developing a cell therapy pipeline of autologous tumor infiltrating lymphocyte, or TIL, therapies for the treatment of patients with cancer. It is also engaged in developing a novel class of genetically engineered TIL therapies using its Co-Stimulatory Antigen Receptor, or CoStAR, platform. Its pipeline includes ITIL-306 which expresses a CoStAR molecule designed to recognize FR?, a tumor-associated antigen that is expressed on numerous solid tumors, including ovarian cancer, uterine cancer, NSCLC, and renal cancer.

Executives

Timothy L. Moore officer: Chief Operating Officer C/O KITE PHARMA, INC., 2225 COLORADO AVE., SANTA MONICA CA 90404

Sumita Ray officer: Chief Legal and Admin Officer C/O PHARMACYCLICS, INC., 995 EAST ARQUES AVENUE, SUNNYVALE CA 94085

Nimish P Shah director 7 BRYANT PARK, 23RD FLOOR, NEW YORK CITY NY 10018

Jack Nielsen director, 10 percent owner C/O AKEBIA THERAPEUTICS, INC., 245 FIRST STREET, SUITE 1100, CAMBRIDGE MA 02142

Vivo Capital Fund Ix, L.p. 10 percent owner 192 LYTTON AVENUE, PALO ALTO CA 94301

Mcgaughy R Kent Jr director 500 CRESCENT COURT, SUITE 250, DALLAS TX 75201

Curative Ventures V Llc 10 percent owner 3963 MAPLE AVENUE, SUITE 390, DALLAS TX 75219

Bronson Crouch director, 10 percent owner, officer: CEO and Chairman C/O INSTIL BIO, INC., 3963 MAPLE AVENUE, SUITE 350, DALLAS TX 75219

Vivo Capital Ix, Llc 10 percent owner 192 LYTTON AVENUE, PALO ALTO CA 94301

Sandeep Laumas officer: CFO and CBO 8480 HONEYCUTT RD, SUITE 200, RALEIGH NC 27615

Neil W Gibson director C/O REGULUS THERAPEUTICS INC., 3545 JOHN HOPKINS COURT SUITE 210, SAN DIEGO CA 92121

Gwendolyn Binder director C/O CABALETTA BIO, INC., 2929 ARCH STREET, SUITE 600, PHILADELPHIA PA 19104

Zachary Roberts officer: Chief Medical Officer C/O INSTIL BIO, INC., 3963 MAPLE AVENUE, SUITE 350, DALLAS TX 75219

George Matcham director C/O INSTIL BIO, INC., 3963 MAPLE AVENUE, SUITE 350, DALLAS TX 75219

Vijay Chiruvolu officer: Chief Technical Officer C/O TURNSTONE BIOLOGICS CORP., 9310 ATHENA CIRCLE, SUITE 300, LA JOLLA CA 92037

Instil Bio Headlines

From GuruFocus

Instil Bio Announces Extension of Cash Runway Beyond 2026 with the Consolidation of R&D Operations to its Manchester, U.K. Site
By Stock market mentor Stock market mentor • 01-31-2023

Instil Bio Announces Oral Presentation of ITIL-306 Preclinical Data at British Society for Gene and Cell Therapy Annual Conference
By Marketwired • 06-26-2023

Instil Bio Reports Second Quarter 2024 Financial Results and Provides Corporate Update
By Marketwired • 08-13-2024

Instil Bio Announces Poster Presentations of CoStAR Platform at the 2022 Society for Immunotherapy of Cancer (SITC) Annual Meeting
By Value_Insider Value_Insider • 11-08-2022

Instil Bio Reports Second Quarter 2023 Financial Results and�Provides Corporate Update
By Marketwired • 08-14-2023

Instil Bio Reports Fourth Quarter and Full Year 2022 Financial Results and Provides Corporate Update
By sperokesalga sperokesalga • 03-31-2023

TIL EQUITY ALERT: ROSEN, A TOP RANKED LAW FIRM, Encourages Instil Bio, Inc. Investors to Inquire About Securities Class Action Investigation � TIL
By Value_Insider Value_Insider • 11-01-2022

Instil Bio Reports Second Quarter 2024 Financial Results and Provides Corporate Update
By GlobeNewswire • 08-13-2024

Newman Ferrara LLP Announces Corporate Governance Investigations of Instil Bio, Inc. (TIL)
By Business Wire Business Wire • 12-12-2022

Analysis of Curative Ventures V LLC's Strategic Reduction in Instil Bio Inc
By GuruFocus News • 10-23-2024

Timothy L. Moore	officer: Chief Operating Officer	C/O KITE PHARMA, INC., 2225 COLORADO AVE., SANTA MONICA CA 90404
Sumita Ray	officer: Chief Legal and Admin Officer	C/O PHARMACYCLICS, INC., 995 EAST ARQUES AVENUE, SUNNYVALE CA 94085
Nimish P Shah	director	7 BRYANT PARK, 23RD FLOOR, NEW YORK CITY NY 10018
Jack Nielsen	director, 10 percent owner	C/O AKEBIA THERAPEUTICS, INC., 245 FIRST STREET, SUITE 1100, CAMBRIDGE MA 02142
Vivo Capital Fund Ix, L.p.	10 percent owner	192 LYTTON AVENUE, PALO ALTO CA 94301
Mcgaughy R Kent Jr	director	500 CRESCENT COURT, SUITE 250, DALLAS TX 75201
Curative Ventures V Llc	10 percent owner	3963 MAPLE AVENUE, SUITE 390, DALLAS TX 75219
Bronson Crouch	director, 10 percent owner, officer: CEO and Chairman	C/O INSTIL BIO, INC., 3963 MAPLE AVENUE, SUITE 350, DALLAS TX 75219
Vivo Capital Ix, Llc	10 percent owner	192 LYTTON AVENUE, PALO ALTO CA 94301
Sandeep Laumas	officer: CFO and CBO	8480 HONEYCUTT RD, SUITE 200, RALEIGH NC 27615
Neil W Gibson	director	C/O REGULUS THERAPEUTICS INC., 3545 JOHN HOPKINS COURT SUITE 210, SAN DIEGO CA 92121
Gwendolyn Binder	director	C/O CABALETTA BIO, INC., 2929 ARCH STREET, SUITE 600, PHILADELPHIA PA 19104
Zachary Roberts	officer: Chief Medical Officer	C/O INSTIL BIO, INC., 3963 MAPLE AVENUE, SUITE 350, DALLAS TX 75219
George Matcham	director	C/O INSTIL BIO, INC., 3963 MAPLE AVENUE, SUITE 350, DALLAS TX 75219
Vijay Chiruvolu	officer: Chief Technical Officer	C/O TURNSTONE BIOLOGICS CORP., 9310 ATHENA CIRCLE, SUITE 300, LA JOLLA CA 92037